

October 03, 2025

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
NSE Symbol: PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001
BSE Scrip Code: 531349

Sub: Receipt of Letter of Award from UNICEF for a Long-Term Agreement for supply of bivalent oral polio vaccine (bOPV) worth ~US\$ 35.65 million for Q2 CY2026 and CY2027.

Reg: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), we are delighted to inform you that Panacea Biotec Limited ("the Company") has received a Letter of Award from UNICEF for a Long-Term Agreement for supply of bivalent oral polio vaccine (bOPV) to UNICEF starting from 1st April 2026 to 31st March 2030.

The total award to the Company is for supply of bOPV in 10 and 20 vial presentation worth ~US\$ 35.65 million (~Rs.315 Crore) for a period of Q2 CY2026 and CY2027.

The requisite details as required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, and other circulars as may be applicable from time to time, is annexed herewith as **Annexure A**.

This is for your kind information and record please.

Thanking you,

Sincerely yours,

For Panacea Biotec Limited

Vinod Goel
Group CFO and Head Legal
& Company Secretary

Details required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. SEBI/HO/CFD/CFD/PoD2/CIR/P/0155 dated November 11, 2024

#	Particulars	Details
a.	Name of the entity awarding the order(s) / contract(s)	United Nations International Children's Emergency Fund (UNICEF)
b.	Significant terms and conditions of order(s)/contract(s) awarded in brief	Award for supply of bivalent oral polio vaccine (bOPV) by Panacea Biotec Limited in Q2 CY2026 and CY2027 subject to applicable conditions. UNICEF will make each award public by publishing the following information on the UNICEF website: • The supplier's name, vaccine(s), duration of award, and total award value, and • awarded prices per supplier per product presentation per year.
c.	Whether order(s) / contract(s) have been awarded by domestic / international entity	International
d.	Nature of order(s) / contract(s)	Supply of bOPV to UNICEF for its requirements as per the orders as may be received from time to time.
e.	Whether domestic or international	International
f.	Time period by which the order(s) / contract(s) is to be executed	Q2 CY2026 and CY2027
g.	Broad consideration or size of the order(s) / contract(s)	~US\$ 35.65 million (~Rs.315 Crore)
h.	Whether the promoter/ promoter group / group companies have any interest in the entity that awarded the order(s) / contract(s)? If yes, nature of interest and details thereof	No
i.	Whether the order(s) / contract(s) would fall within related party transactions? If yes, whether the same is done at "arm's length"	No

This is for your kind information and record please.

Thanking you,

Sincerely yours,

For **Panacea Biotec Limited**

Vinod Goel

Group CFO and Head Legal & Company Secretary